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Short-term Acipimox decreases the ability of plasma
from Type 2 diabetic patients and healthy subjects to
stimulate cellular cholesterol ef¯ux: a potentially
adverse effect on reverse cholesterol transport
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Abstract
Aims To evaluate the effect of short-term administration of the anti-lipolytic
agent, Acipimox, on the ability of plasma to stimulate cellular cholesterol
removal, which represents one of the ®rst steps in the anti-atherogenic process
of reverse cholesterol transport.
Methods Eight male Type 2 diabetic patients and eight healthy subjects were
studied after a 12-h fast at baseline, after 24 h of Acipimox administration,
250 mg every 4 h, and again after 1 week (recovery). Plasma lipids,
apolipoprotein AI, phospholipid transfer protein (PLTP) activity, pre-b high-
density lipoproteins (HDL) in incubated plasma and ef¯ux of radiolabelled
cholesterol from Fu5AH rat hepatoma cells to plasma were measured at each
time point.
Results Acipimox lowered plasma triglycerides in diabetic patients
(P = 0.001) and healthy subjects (P = 0.002), whereas plasma non-esteri®ed
fatty acids were decreased in diabetic patients (P = 0.001) compared with the
averaged values at baseline and recovery. Acipimox decreased HDL
cholesterol in healthy subjects (P = 0.007) and plasma apolipoprotein AI in
both groups (P = 0.001 for diabetic patients; P = 0.008 for healthy subjects).
Not only plasma PLTP activity (P = 0.001 for diabetic patients; P = 0.01 for
healthy subjects), but also pre-b HDL in incubated plasma (P = 0.001 for
diabetic patients; P = 0.03 for healthy subjects) and cellular cholesterol ef¯ux
to plasma (P = 0.04 for diabetic patients; P = 0.005 for healthy subjects) were
lowered by Acipimox in both groups.
Conclusions Short-term Acipimox administration impairs the ability of
plasma from Type 2 diabetic patients and healthy subjects to stimulate cellular
cholesterol ef¯ux, in conjunction with alterations in HDL parameters and in
PLTP activity. If the impairment of cellular cholesterol ef¯ux to plasma is
sustained with long-term treatment, this potentially adverse effect should be
considered when treating diabetic dyslipidaemia with Acipimox.
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Introduction
The cardioprotective effect of high density lipoproteins
(HDL) [1] is commonly explained by the role of HDL in
reverse cholesterol transport [2]. By this process choles-
terol is removed from peripheral cells by HDL and then
transported to the liver for metabolism and excretion.
Ef¯ux of free cholesterol from cell membranes to extra-
cellular acceptors is one of the ®rst steps in reverse
cholesterol transport [3]. The mechanisms responsible for
cellular cholesterol removal are complex and still incom-
pletely understood [4,5]. Lipid-poor pre-b HDL particles
are considered to represent the initial acceptors of cellular
cholesterol [6,7]. Among other factors, plasma phospho-
lipid transfer protein (PLTP) is involved in HDL remodel-
ling. This lipid transfer protein converts HDL in smaller
and larger particles [8], and during this process pre-b HDL
particles are generated [7,9]. Over-expression of human
PLTP in mice enhances pre-b HDL generation and inhibits
cholesterol accumulation in macrophages [9]. PLTP may
also promote cellular cholesterol removal via binding to
the cell membrane [10]. Cholesterol ef¯ux out of Fu5AH
rat hepatoma cells, a well-validated cell culture system
[4,11], is positively correlated with PLTP activity in human
plasma [12]. This indeed suggests that a high PLTP activity
enhances the potential of plasma to promote cellular
cholesterol removal. It was recently shown that plasma
PLTP activity is lowered after 24 h administration of the
anti-lipolytic agent, Acipimox [13], a drug used to ameli-
orate diabetic dyslipidaemia. We hypothesized that an
Acipimox-induced decrease in plasma PLTP activity would
result in less pre-b HDL generation and in a diminished
cellular cholesterol ef¯ux-promoting capacity of plasma.
In the present study, we document the effect of 24 h
Acipimox administration on the ability of plasma from
Type 2 diabetic patients and healthy subjects to stimulate
cellular cholesterol removal, as well as on pre-b HDL
generation.
Patients and methods
The study was approved by the medical ethics committee and
informed consent was obtained from all subjects. Eight male
patients with Type 2 diabetes mellitus [14], and eight healthy
men participated. Subjects with clinically manifest cardiovas-
cular disease, renal disease (serum creatinine > 120 mmol/l or
microalbuminuria > 20 mg/min), blood pressure > 160/
95 mmHg, thyroid dysfunction, liver disease and smokers
were excluded. Maximal alcohol allowance was three beverages
per day. Four diabetic patients used sulphonylurea and four
patients received sulphonylurea and metformin. No other drugs
were used. The subjects were studied at baseline, after 24 h of
Acipimox administration, 250 mg every 4 h, and again after
1 week (recovery). They refrained from alcohol and strenuous
physical activity during 24 h before blood sampling. On each
occasion venous blood was obtained after a 12-h fast. The
participants consumed their habitual diet and the diabetic
patients continued their blood glucose-lowering drugs during
the study period. Body mass index (BMI, in kg/m2) was
calculated as weight divided by height squared.
Laboratory methods
Venous blood was collected into EDTA (1.5 mg/ml)-containing
tubes. Plasma was separated immediately at 4°C and stored at
±80°C. Plasma non-esteri®ed fatty acids (NEFA), triglycerides
and cholesterol were measured enzymatically [15]. Apo B-
containing lipoproteins were precipitated with polyethylene
glycol-6000 and HDL cholesterol was measured in the super-
natant [15]. Plasma apolipoprotein (apo) A1 was assayed by
immunoturbidimetry [15]. Plasma pre-b HDL generation was
measured after incubation of plasma at 37°C for 16 h under
conditions of lecithin:cholesterol acyltransferase inhibition with
1 mmol/l iodoacetate [9,16] and was expressed as its apo AI
concentration in g/l. a HDL and pre-b HDL were separated
using one-dimensional agarose electrophoresis with inclusion of
a reference sample with a known amount of pre-b HDL (0.171 g
of apo AI per ml in pre-b HDL) on each gel. This was done
because different plasma dilutions may give rise to different
proportions of pre-b HDL and a HDL [17]. Four-fold diluted
plasma samples (3 ml) were loaded on the gels. The HDL
subfractions were separated at 100 V during 1 h, followed by
blotting on nitrocellulose membranes. After 1 h at room
temperature in blocking buffer, the membranes were incubated
with 100-fold diluted rabbit anti-human apo AI during 1 h,
followed by overnight incubation at 4°C. Subsequently, the
membranes were extensively washed, followed by 3 h incuba-
tion at room temperature with 1000-fold diluted donkey
125I-labelled anti-rabbit F(ab¢)2 fragments. Thereafter, the
nitrocellulose membranes were extensively washed and dried
in air, followed by quanti®cation of radioactivity in pre-b HDL.
Plasma PLTP activity was measured by a radioisotopic
method using a phospholipid vesicles-HDL system as described
[15,18]. Plasma PLTP activity levels are linearly correlated with
the amount of plasma added to the incubation system and were
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expressed as percentage of the activity in a human reference
plasma. Cellular cholesterol ef¯ux to plasma was measured
using Fu5AH rat hepatoma cells as described [11]. Fu5AH cells
were grown to con¯uence in the presence of 3H-cholesterol.
After removal of the culture medium containing the radiola-
belled cholesterol, the cells were allowed to equilibrate for 24 h.
Thereafter, ef¯ux of radiolabelled cholesterol from cells was
determined during 4 h of incubation at 37°C with 20-fold
diluted plasma samples, originally containing 50 U/mL of
heparin. The radioactivity in the medium was then counted,
and cholesterol ef¯ux was expressed as percentage of the
radioactivity initially present in the cells (fractional ef¯ux). Data
were corrected for the small amount of radiolabel in the medium
in the absence of plasma. Similar ef¯ux values were found with
plasma and serum (data not shown). Fractional cholesterol
ef¯ux is a measure of the ability of a speci®c plasma to remove
cholesterol from the cell membrane. Glycated haemoglobin
(HbA1c) was measured by high-performance liquid chromato-
graphy (BioRad, Veenendaal, The Netherlands; reference range
4.6±6.1%). Blood glucose was measured on an APEC glucose
analyser (APEC Inc., Danvers, MA, USA).
Statistical analysis
Data are given in mean 6 SD or in geometric mean (95%
con®dence interval (CI)). Changes in variables after Acipimox
were compared with the averaged values at baseline and
recovery by paired Student's t-tests and are given in mean
(95% CI). Between group differences in baseline variables and
between group differences in changes in variables after
Acipimox were evaluated by unpaired Student's t-tests. P
< 0.05 was considered signi®cant. On the basis of a day-to-day
coef®cient of variation of cellular cholesterol ef¯ux to plasma of
6.0%, it was estimated that with eight participants a relative
change in cellular cholesterol ef¯ux to plasma of 6.0% could be
Table 1 Blood glucose, plasma (apo)lipoprotein variables, non-esteri®ed fatty acids (NEFA), phospholipid transfer protein (PLTP) activity and
cholesterol ef¯ux from Fu5AH cells to plasma after 24 h Acipimox administration in eight Type 2 diabetic patients and eight healthy subjects
Baseline Acipimox Recovery Change after Acipimox
P-value for
between group
difference in change
Blood glucose (mmol/l)
Type 2 diabetic patients 7.8 6 1.5* 6.4 6 0.9 7.9 6 1.9 ±1.4 (±2.3 to ±0.6) P = 0.005 P = 0.007
Healthy subjects 4.3 6 0.4 4.2 6 0.5 4.3 6 0.7 ±0.1 (±0.3±0.1) P = 0.21
Plasma triglycerides (mmol/l)
Type 2 diabetic patients 1.81** 1.29 1.66 ±0.48 (±0.71 to ±0.25) P = 0.001 P = 0.03
(1.46±2.25) (1.02±1.64) (1.19±2.31)
Healthy subjects 0.97 0.68 0.87 ±0.23 (±0.30 to ±0.15) P = 0.002
(0.64±1.18) (0.41±1.12) (0.63±1.20)
Plasma NEFA (mmol/l)
Type 2 diabetic patients 1.29 6 0.44*** 0.31 6 0.08 1.14 6 0.23 ±0.90 (±1.11 to ±0.69) P = 0.001 P = 0.001
Healthy subjects 0.64 6 0.30 0.52 6 0.26 0.67 6 0.27 ±0.14 (±0.30±0.03) P = 0.08
HDL cholesterol (mmol/l)
Type 2 diabetic patients 0.98 6 0.15 0.93 6 0.13 1.01 6 0.18 ±0.06 (±0.14±0.01) P = 0.08 P = 0.77
Healthy subjects 1.12 6 0.31 1.06 6 0.34 1.15 6 0.41 ±0.07 (±0.12 to ±0.03) P = 0.007
Plasma apo AI (g/l)
Type 2 diabetic patients 1.24 6 0.11 1.15 6 0.10 1.21 6 0.09 ±0.08 (±0.10 to ±0.06) P = 0.001 P = 0.90
Healthy subjects 1.21 6 0.20 1.16 6 0.21 1.27 6 0.26 ±0.08 (±0.14 to ±0.03) P = 0.008
Pre-b HDL in incubated plasma (apo AI, g/l)
Type 2 diabetic patients 0.18 6 0.03 0.11 6 0.03 0.16 6 0.06 ±0.06 (±0.07 to ±0.04) P = 0.001 P = 0.60
Healthy subjects 0.16 6 0.09 0.09 6 0.05 0.11 6 0.06 ±0.05 (±0.09 to ±0.01) P = 0.03
Plasma PLTP activity (% of reference plasma)
Type 2 diabetic patients 87.0 6 5.9 81.3 6 9.5 91.8 6 10.1 ±8.1 (±11.2 to ±5.0) P = 0.001 P = 0.58
Healthy subjects 93.8 6 19.1 84.0 6 13.5 94.2 6 15.0 ±10.0 (±17.0 to ±2.9) P = 0.01
Cellular cholesterol ef¯ux (%/4 h)
Type 2 diabetic patients 31.4 6 2.7 29.7 6 2.5 30.8 6 2.6 ±1.4 (±2.8 to ±0.1) P = 0.04 P = 0.80
Healthy subjects 29.9 6 3.0 28.3 6 2.7 29.1 6 2.5 ±1.3 (±2.0 to ±0.5) P = 0.005
Data are given in mean 6 SD, except for plasma triglycerides which are given in geometric mean (95% con®dence interval).
Changes in variables after Acipimox are compared with the averaged values at baseline and recovery and are given in mean (95% con®dence
interval).
*P = 0.001; **P = 0.01; ***P = 0.002 from healthy subjects at baseline.
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demonstrated with a power of 0.80 and a two-sided P-value
< 0.05.
Results
Age was not different between Type 2 diabetic patients and
healthy subjects (58 6 7 vs. 52 6 9 years, P = 0.11),
whereas BMI (27.7 6 1.6 kg/m2 vs. 24.7 6 2.3 kg/m2,
P = 0.003) and HbA1c (7.1 6 0.8% vs. 5.1 6 0.3%,
P = 0.001) were higher in diabetic patients than in healthy
subjects. Blood glucose decreased after Acipimox in
diabetic patients, but not in healthy subjects (Table 1).
Baseline plasma cholesterol was 5.4 6 0.6 and
4.7 6 0.8 mmol/l in diabetic and healthy subjects, respect-
ively (P = 0.06). Baseline plasma triglycerides and NEFA
levels were higher in diabetic compared with healthy
subjects (Table 1). HDL cholesterol, plasma apo AI, pre-b
HDL in incubated plasma, PLTP activity and cholesterol
ef¯ux from Fu5AH cells to plasma at baseline were not
signi®cantly different between the groups. Blood glucose
decreased after Acipimox in diabetic patients, but not in
healthy subjects (Table 1). Plasma triglycerides were
lowered by Acipimox in both groups. The decrease in
plasma NEFA was signi®cant in diabetic patients. The
changes in blood glucose, plasma triglycerides and NEFA
in response to Acipimox were larger in diabetic patients
than in healthy subjects. Acipimox administration resulted
in a decrease in HDL cholesterol in healthy subjects, as well
as in a decrease in plasma apo AI, plasma PLTP activity and
pre-b HDL generation in both groups (Table 1). Of
interest, cellular cholesterol ef¯ux to plasma from both
diabetic patients and healthy subjects was decreased by
Acipimox (Table 1). The changes in these variables in
response to Acipimox were similar in both groups.
Discussion
Using Fu5AH cells as model system, this study shows a
similar impairment in the ability of plasma from Type 2
diabetic patients and healthy subjects to promote cellular
cholesterol ef¯ux after 24 h of Acipimox administration.
As expected [13], plasma PLTP activity decreased in both
groups in response to this treatment. A novel ®nding of our
study is that the generation of pre-b HDL particles, as
measured in incubated plasma, is also decreased after
Acipimox in Type 2 diabetic patients and in healthy
subjects. Previous studies have demonstrated that apart
from the HDL cholesterol and HDL phospholipid concen-
tration, plasma apo AI, pre-b HDL and plasma PLTP
activity are determinants of cellular cholesterol ef¯ux
[4,6,7,9,11,12]. The diminished cellular cholesterol ef¯ux
to plasma after Acipimox could thus be due to the decrease
in plasma PLTP activity which may result in less pre-b HDL
generation [7,9], to the slight decrease in plasma apo AI
and in HDL cholesterol, or to a combination of these
changes. The presently studied Type 2 diabetic patients
were not matched with healthy subjects for plasma lipid
levels. Plasma triglyceride and NEFA concentrations at
baseline were higher and the decreases in these variables in
response to Acipimox were larger in Type 2 diabetic
patients than in healthy subjects. Baseline levels of HDL
cholesterol, plasma apo AI, pre-b HDL in incubated
plasma and plasma PLTP activity were, however, not
different between diabetic patients and healthy subjects.
Likewise, cellular cholesterol ef¯ux at baseline was similar
in both groups. In comparison, cholesterol ef¯ux out of
Fu5AH cells has been reported to be impaired in Type 2
diabetic patients with a low HDL cholesterol [12].
The acute plasma triglyceride lowering effect of
Acipimox in diabetic patients [19, present study] is
sustained with long-term treatment [20±22]. HDL choles-
terol remains unchanged [20±22] or tends to increase [23±
25] with its prolonged use. Although hypertriglyceridae-
mia is an independent cardiovascular risk factor [26], the
potential cardioprotective effect of Acipimox remains to be
proven. An impairment in reverse cholesterol transport, as
re¯ected by a low capacity of plasma to stimulate cellular
cholesterol removal, probably represents an atherogenic
phenomenon [2±4,27]. Further studies are therefore war-
ranted to document whether the decrease in cellular
cholesterol ef¯ux to plasma persists with prolonged
Acipimox treatment. If this potentially adverse effect on
reverse cholesterol transport is sustained, it should be
taken into account when treating diabetic dyslipidaemia
with this anti-lipolytic agent.
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